Federal Register Notice: FDA has determined that the regulatory review period for Amgen’s Kineret (anakinra) is 4,101 days for extending a patent claiming that human biological product. Kineret is indicated for reducing signs and symptoms of moderately to severely active rheumatoid arthritis in patients 18 years or older who have failed one or more disease-modifying antirheumatic drugs. To view this notice, click here.